A retrospective cohort study of 13,108 adults found no increased risk of major adverse cardiovascular events following exposure to nicotinamide, a water-soluble form of vitamin B3 used in skin cancer prevention. The study included predominantly male participants, with no statistically significant difference in major adverse cardiovascular events (MACE) incidence between nicotinamide users and non-users. Stratified analyses found no significant association between nicotinamide exposure and MACE among immunosuppressed patients or across different exposure durations. The study addresses concerns raised by previous research and has clinical implications for patients using nicotinamide for skin cancer chemoprevention, particularly high-risk groups such as organ transplant recipients.

Source: JAMA Dermatology